Skip to main content
63°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Immuron Limited
< Previous
1
2
Next >
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
November 28, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron CEO Steven Lydeamore Investor Webinar Presentation
November 13, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron CEO Steven Lydeamore presented at AusBioInvest
October 30, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron Announces Travelan® Clinical Study Cohort 2 commences
October 18, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron achieves record quarterly Travelan® sales
October 11, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron achieves record monthly Travelan® sales
September 13, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright
September 11, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron to present at the Military Health System Research Symposium
August 14, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron Announces First Patients Enrolled in Travelan® Clinical Study
July 25, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron CEO, Steven Lydeamore to present at Bioshares
July 24, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron Business Update - Ateria Health launches Juvia™ in Australia
July 11, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron FY23 Sales increase 136% on FY22 Sales
July 05, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron Chairman Transition
June 30, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
ASX:PNV
IMRN
Immuron Business Update: Letter to Shareholders
June 22, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron Initiates Recruitment of Travelan® Clinical Study
May 30, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation
May 08, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron CEO, Steven Lydeamore to present at Coffee Microcaps
May 02, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron Q3 FY23 Business Update Presentation
April 19, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Q3 FY23 Business Update Webinar Notification
April 11, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron Q3 Sales reach 150% of 1H Sales
April 06, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron CEO, Steven Lydeamore to host an investor webinar
February 15, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic
January 25, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone
January 18, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease
January 17, 2023
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron Receives FDA Approval for Travelan IND Application
December 23, 2022
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron Submits IND Application To FDA for Travelan
December 05, 2022
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron completes strategic investment in leading gut health biotech Ateria Health
November 16, 2022
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron CEO, Steven Lydeamore to present at AusBioInvest
October 26, 2022
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron strategic investment in leading gut health biotech Ateria Health
October 13, 2022
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
October 04, 2022
From
Immuron Limited
Via
GlobeNewswire
Tickers
ASX:IMC
IMRN
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
